# Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

> **NCT02601014** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 32 (actual)

## Conditions studied

- Prostate Cancer
- Recurrent Prostate Carcinoma
- Stage IV Prostate Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02601014
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-15
- **Primary completion:** 2020-12-03
- **Final completion:** 2021-10-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601014, "Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02601014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*